EAN 2025 | Silent progression in patients with MS: the importance of early detection

Now we see that our patients are progressing, but they are without relapses. So that before, the patients had a lot of relapses, and after the relapses they were not improving completely, so that the patients had some symptoms. And these accumulations of symptoms were causing the progression. But now we have a very good treatment and we can stop the relapses. And despite this, despite the fact that we have no relapses, our patients are worsening very slowly but they are still worsening. And we have realized that this worsening is independent of the relapses. Because now we have such good treatments that we can stop all the inflammation, now we need to look for treatments that can stop the progression. Because we have realized that this silent progression, we need to look for treatments that can stop this silent progression. But the first important thing is to first determine how to detect this progression. And to detect this progression in a very early way. Because when we detect the progression and it is too late, the treatments will not be useful. So that now we are trying to find tools that we can detect very early the progression. Like new tools like digital tools, like new biomarkers in blood, like new lesions in MRI, new kinds of lesions in MRI. And after that, we can have some of these biomarkers and some tools, we can use the new treatments because next year we will approve and commercialize the first treatment for the progression. So that we need to be ready to have enough tools that we can detect the progression earlier than before so that we can use the new treatments in the right patients and at the right moment.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.